MedPath

Atorvastatin in Major Depressive Disorder

Phase 3
Recruiting
Conditions
Major Depressive Disorder.
Major depressive disorder, recurrent, mild
F33.0
Registration Number
IRCT20220127053839N1
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
144
Inclusion Criteria

?Age 20 to 55 years
?People with Major depressive disorder based on DSM-5 Criteria and clinical interview
?Lack of obvious and serious medical illness based on medical history, medications used, and history of hospitalization in a clinical interview
?Use of any agent or drugs that may have any interactions with sertralin or atorvastatin pharmacokineticlly or pharmacodinamiclly.
?Absence of active suicidal thoughts
?Absence of psychotic symptoms
?No symptoms of severe anxiety or panic disorder based on history and patients self report
?Having Hamilton rating scale for depression above 7 at the beginning of treatment

Exclusion Criteria

?Existence of a serious uncontrolled medical condition based on medical history, medication use, and history of hospitalization in clinical interviews such as hypo and hyperthyroidism, epilepsy, diabetes, hypertension
?Co-occurrence of other obvious psychiatric disorders including bipolar or mixed mood disorders, severe anxiety disorders, and psychosis
?Existence of symptoms of severe anxiety or panic based on the statements of the patient and their companions in the clinical interview
?History of the mania Period
?Existence of psychotic symptoms associated with depression
?People with suicidal acts or thoughts or suicides at the start of the study
?Contraindications to atorvastatin
?Long-term use of psychiatric and non-psychiatric drugs that interfere with the drugs prescribed in this study
?Take other non-steroidal anti-inflammatory drugs now
?Active and current history of alcohol or drug use
?People with mental retardation or other cognitive and neurological disorders such as delirium, uncontrolled seizures, head trauma, seizure disorders (other than those associated with fever), and neurodegenerative diseases.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression severity score in Hamilton Rating Scale for depression. Timepoint: Before intervention and 4, 8 weeks after intervention. Method of measurement: Hamilton Rating Scale And DSM5 Criteria.
Secondary Outcome Measures
NameTimeMethod
Depression severity score in Hamilton Rating Scale for depression. Timepoint: Before intervention and 4,8 weeks after intervention. Method of measurement: Hamilton Rating Scale for depression.
© Copyright 2025. All Rights Reserved by MedPath